FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2821630866> ?p ?o ?g. }

• W2821630866 abstract "Cisplatin is one of the major drugs that used in the treatment of osteosarcoma. Cisplatin exerts its function by making cisplatin-DNA adducts culminating in cellular death. These adducts found to be repaired by nucleotide excision repair (NER) pathway. This study aimed to evaluate if polymorphisms in two main genes in the NER pathway, excision repair cross-complementing group 1 and 2 (ERCC1 and ERCC2) could affect the histological response to cisplatin based chemotherapy or clinical outcomes, particularly, event free survival (EFS) and overall survival (OS) rates.ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy. DNA was extracted from patient's formalin-fixed paraffin-embedded (FFPE) samples, patient's genotypes were determined by using polymerase chain reaction-restriction fragment length polymorphism PCR-RFLP assay. The distribution of the patients' genotype and the allele frequencies were reported. The association between each of these genotypes and many clinical and patho-histological parameters (e.g. EFS, OS and patho-histological response to treatment) was examined. The associations between gender, tumor location, presence of metastasis at diagnosis, histological subtypes, and type of neoadjuvant chemotherapy and between the histological response, EFS and OS rates were also examined.This study revealed that there was a positive and significant association between ERCC1 C8092 A genotypes and median EFS rate in years; patients who were carriers of C allele (CC & CA) were found to have longer EFS rates than patients with AA genotype (P value = 0.006) and the median EFS rates were respectively as following: 2.04, 0.24 years. As well, both the presence of metastasis and the histological subtype at the time of diagnosis, were able to affect the EFS rate but not the OS. However, there was a positive correlation between OS rate and the patients' primary response to treatment.Our results suggested that ERCC1 8092 C allele may play a role as a candidate prognostic marker in patients with osteosarcoma." @default.
• W2821630866 created "2018-07-19" @default.
• W2821630866 creator A5021001103 @default.
• W2821630866 creator A5042638502 @default.
• W2821630866 creator A5051139582 @default.
• W2821630866 creator A5070151087 @default.
• W2821630866 creator A5086092215 @default.
• W2821630866 date "2018-07-06" @default.
• W2821630866 modified "2023-09-24" @default.
• W2821630866 title "The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients" @default.
• W2821630866 cites W102310467 @default.
• W2821630866 cites W14799966 @default.
• W2821630866 cites W1507528652 @default.
• W2821630866 cites W1621930076 @default.
• W2821630866 cites W1908561757 @default.
• W2821630866 cites W1961187943 @default.
• W2821630866 cites W1979694104 @default.
• W2821630866 cites W1987604182 @default.
• W2821630866 cites W1988325237 @default.
• W2821630866 cites W2002261573 @default.
• W2821630866 cites W2011551652 @default.
• W2821630866 cites W2012006201 @default.
• W2821630866 cites W2014966556 @default.
• W2821630866 cites W2036706547 @default.
• W2821630866 cites W2046888031 @default.
• W2821630866 cites W2049903904 @default.
• W2821630866 cites W2050258759 @default.
• W2821630866 cites W2058990823 @default.
• W2821630866 cites W2078339029 @default.
• W2821630866 cites W2079620909 @default.
• W2821630866 cites W2099154608 @default.
• W2821630866 cites W2105826438 @default.
• W2821630866 cites W2113363667 @default.
• W2821630866 cites W2124227044 @default.
• W2821630866 cites W2130955870 @default.
• W2821630866 cites W2131112855 @default.
• W2821630866 cites W2132336832 @default.
• W2821630866 cites W2139687160 @default.
• W2821630866 cites W2142506362 @default.
• W2821630866 cites W2153906296 @default.
• W2821630866 cites W2163731055 @default.
• W2821630866 cites W2164370613 @default.
• W2821630866 cites W2166509493 @default.
• W2821630866 cites W2168655513 @default.
• W2821630866 cites W2397338589 @default.
• W2821630866 cites W2411296832 @default.
• W2821630866 cites W2412967379 @default.
• W2821630866 cites W2417686086 @default.
• W2821630866 cites W2736312748 @default.
• W2821630866 cites W4241299745 @default.
• W2821630866 doi "https://doi.org/10.1186/s12881-018-0627-4" @default.
• W2821630866 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6035436" @default.
• W2821630866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29980176" @default.
• W2821630866 hasPublicationYear "2018" @default.
• W2821630866 type Work @default.
• W2821630866 sameAs 2821630866 @default.
• W2821630866 citedByCount "9" @default.
• W2821630866 countsByYear W28216308662019 @default.
• W2821630866 countsByYear W28216308662020 @default.
• W2821630866 countsByYear W28216308662021 @default.
• W2821630866 countsByYear W28216308662022 @default.
• W2821630866 countsByYear W28216308662023 @default.
• W2821630866 crossrefType "journal-article" @default.
• W2821630866 hasAuthorship W2821630866A5021001103 @default.
• W2821630866 hasAuthorship W2821630866A5042638502 @default.
• W2821630866 hasAuthorship W2821630866A5051139582 @default.
• W2821630866 hasAuthorship W2821630866A5070151087 @default.
• W2821630866 hasAuthorship W2821630866A5086092215 @default.
• W2821630866 hasBestOaLocation W28216308661 @default.
• W2821630866 hasConcept C104317684 @default.
• W2821630866 hasConcept C104451858 @default.
• W2821630866 hasConcept C126322002 @default.
• W2821630866 hasConcept C134935766 @default.
• W2821630866 hasConcept C135763542 @default.
• W2821630866 hasConcept C143998085 @default.
• W2821630866 hasConcept C153209595 @default.
• W2821630866 hasConcept C180754005 @default.
• W2821630866 hasConcept C2776694085 @default.
• W2821630866 hasConcept C2777760704 @default.
• W2821630866 hasConcept C2778239845 @default.
• W2821630866 hasConcept C2778883343 @default.
• W2821630866 hasConcept C2779309665 @default.
• W2821630866 hasConcept C502942594 @default.
• W2821630866 hasConcept C54355233 @default.
• W2821630866 hasConcept C71924100 @default.
• W2821630866 hasConcept C86803240 @default.
• W2821630866 hasConceptScore W2821630866C104317684 @default.
• W2821630866 hasConceptScore W2821630866C104451858 @default.
• W2821630866 hasConceptScore W2821630866C126322002 @default.
• W2821630866 hasConceptScore W2821630866C134935766 @default.
• W2821630866 hasConceptScore W2821630866C135763542 @default.
• W2821630866 hasConceptScore W2821630866C143998085 @default.
• W2821630866 hasConceptScore W2821630866C153209595 @default.
• W2821630866 hasConceptScore W2821630866C180754005 @default.
• W2821630866 hasConceptScore W2821630866C2776694085 @default.
• W2821630866 hasConceptScore W2821630866C2777760704 @default.
• W2821630866 hasConceptScore W2821630866C2778239845 @default.
• W2821630866 hasConceptScore W2821630866C2778883343 @default.
• W2821630866 hasConceptScore W2821630866C2779309665 @default.
• W2821630866 hasConceptScore W2821630866C502942594 @default.

• next